Table 2. Immunogenicity profile of intradermal vaccines in elderly.
| Authors |
No. of subjects (intradermal) |
Age range |
Study year |
Intradermal antigen dose |
Immunogenicity (CHMP criteria) |
||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Seroprotection rate (%) | Seroconversion rate (%) | GMT ratio | |||||||||||
| |
|
|
|
|
H1N1 |
H3N2 |
B |
H1N1 |
H3N2 |
B |
H1N1 |
H3N2 |
B |
| Belshe |
102 (56) |
>60 y |
2001–02 |
6 µg |
100.0 |
92.9 |
100.0 |
17.9 |
16.1 |
17.9 |
1.9 |
2.1 |
2.0 |
| Holland |
1101 (366) |
>60 y |
2006 |
15 µg |
>70 |
>90 |
>80 |
>40 |
>40 |
>40 |
>3 |
>4 |
>3 |
| |
1101 (369) |
>60 y |
2006 |
21 µg |
>80 |
>90 |
>80 |
>40 |
>40 |
>40 |
>4 |
>5 |
>4 |
| Arnou |
3685 (2604) |
>60 y |
2006 |
15 µg |
>70 |
>90 |
>50 |
>30 |
>60 |
>30 |
>3 |
>8 |
>3 |
| |
407 (133) |
>60 y |
2007 |
15 µg |
95.5 |
98.5 |
55.6 |
74.2 |
36.6 |
14.3 |
9.64 |
2.92 |
1.77 |
| |
468 (121) |
>60 y |
2008 |
15 µg |
81.8 |
92.6 |
70.2 |
37.2 |
73.6 |
47.1 |
2.88 |
8.45 |
3.76 |
| Van Damme | 790 (395) | >65 y | 2007 | 15 µg | 81.3 | >90 | >50 | >60 | >40 | >20 | >8 | >4 | >2 |